Cytokine Signalling Forum

Publications





May 18

Tofacitinib dans la polyarthrite rhumatoïde: le manque de changement précoce dans l'activité de la maladie prédit une faible probabilité d’atteindre une activité faible de la maladie au 6ème mois

Van Vollenhoven RF, Lee EB, Fallon L, Zwillich SH, Wilkinson B, Chapman D, Demasi R, Keystone E.
Arthritis Care Res (Hoboken) 2019 Jan;71(1):71-79. DOI: 10.1002/acr.23585

This post-hoc analysis of two, Phase 3 studies, ORAL Start and ORAL Standard shows that early treatment response can predict long-term disease activity outcomes. EULAR recommendations suggest that treat-to-target strategies require regular target assessments with treatment approaches changed if targets are not reached at 6 months. To optimize this strategy, therapy outcomes should be known, and the relationship between short and long-term outcomes defined. The current analysis focused on the d...

Mots clefs: JAK, Tofacitinib, Clinical, Efficacy

Traduit par: Helena Farese